Pancreatic Cancer Research

ResearcherTongji HospitalActive in the last 2 years

Taoyuan Yin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-0838-9746; OpenAlex author ID A5062629980. Sources: OpenAlex.

Their work

Papers
8 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2019: 1 paper · 2020: none · 2021: none · 2022: 4 papers · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 8

  1. Phosphorylation-dependent STAMBP drives the progression of pancreatic ductal adenocarcinoma by deubiquitinating and stabilizing BAG3. Co-author DOI 10.1038/s41418-026-01665-1↗
  2. A self-amplifying USP14-TAZ loop drives the progression and liver metastasis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41418-022-01040-w↗
  3. An E3 ubiquitin-proteasome gene signature for predicting prognosis in patients with pancreatic cancer. Co-author DOI 10.3389/fimmu.2023.1332626↗
  4. Hypoxia activated HGF expression in pancreatic stellate cells confers resistance of pancreatic cancer cells to EGFR inhibition. Co-author DOI 10.1016/j.ebiom.2022.104352↗
  5. Comparison of laparoscopic versus open pancreaticoduodenectomy in patients with resectable pancreatic ductal adenocarcinoma: A propensity score-matching analys… First author DOI 10.1016/j.pan.2021.12.005↗
  6. Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: study protocol for a multicentre randomised controlled trial. Co-author DOI 10.1136/bmjopen-2021-057128↗
  7. LncRNA FAM83H-AS1 promotes the malignant progression of pancreatic ductal adenocarcinoma by stabilizing FAM83H mRNA to protect β-catenin from degradation. Co-author DOI 10.1186/s13046-022-02491-2↗
  8. Long noncoding RNA LINC01111 suppresses pancreatic cancer aggressiveness by regulating DUSP1 expression via microRNA-3924. Co-author DOI 10.1038/s41419-019-2123-y↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shutao Pan · 8 shared papers, 2019–2026 · strength 1.23
  2. Min Wang · 8 shared papers, 2019–2026 · strength 1.23
  3. Renyi Qin · 6 shared papers, 2019–2026 · strength 0.93
  4. Zhenxiong Zhang · 5 shared papers, 2022–2026 · strength 0.89
  5. Jun Gong · 4 shared papers, 2022–2026 · strength 0.71
  6. Chunle Zhao · 4 shared papers, 2022–2026 · strength 0.67
  7. Min Zhou · 3 shared papers, 2023–2026 · strength 0.58
  8. Yongkang Shi · 3 shared papers, 2022–2026 · strength 0.55
  9. Xingjun Guo · 4 shared papers, 2019–2023 · strength 0.51
  10. Min Zhou · 3 shared papers, 2019–2022 · strength 0.35
  11. Yu Bai · 1 shared paper, 2026 · strength 0.26
  12. Xiuhui Shi · 2 shared papers, 2019–2022 · strength 0.22
  13. Ruizhi He · 2 shared papers, 2019–2022 · strength 0.22
  14. Renyi Qin · 1 shared paper, 2022 · strength 0.17
  15. Yuhui Liu · 1 shared paper, 2023 · strength 0.16
  16. Renyi Qin · 1 shared paper, 2022 · strength 0.13
  17. Xuemin Chen · 1 shared paper, 2022 · strength 0.13
  18. Jingdong Li · 1 shared paper, 2022 · strength 0.13
  19. Yahui Liu · 1 shared paper, 2022 · strength 0.13
  20. Jun Liu · 1 shared paper, 2022 · strength 0.13
  21. Xianjun Yu · 1 shared paper, 2022 · strength 0.13
  22. Yuqing Zhang · 1 shared paper, 2022 · strength 0.12
  23. Yan Zhao · 1 shared paper, 2022 · strength 0.12
  24. Min Li · 1 shared paper, 2022 · strength 0.12
  25. Yuhui Liu · 1 shared paper, 2022 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.